Merck (MRK) said Thursday its late-stage trial evaluating its cancer drug Keytruda in combination with chemotherapy with or without bevacizumab met its primary endpoint of progression-free survival in patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers.
The trial also met a secondary endpoint of overall survival in patients whose tumors express PD-L1, the company said.
The trial showed no new safety signals for Keytruda as the safety profile remained consistent with that observed in previously reported studies.
Merck said the study is continuing and that the final overall survival results for the entire study population will be evaluated at a future analysis.
The company's shares were up about 1% in recent premarket activity on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.